Nirma acquires majority stake in Glenmark Life Sciences

Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals

Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma for Rs. 5,652 Cr

Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction

Margins under pressure; domestic market growth to slow down: Nirmal Bang

A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report

Budget 2026-27: Government to establish 5 regional medical hubs to boost medical tourism

Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub

A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave

Enanta files patent infringement suit against Pfizer

The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists

Glenmark Nutrition Awards 2025 celebrates innovation and impact in fight against malnutrition

403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.

Glenmark Life Sciences rebranded as Alivus Life Sciences

The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space